Trending Topic

roflilumast foam
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The FDA recently approved roflumilast 0.3% foam for the treatment of plaque psoriasis of the scalp and body in both adolescents and adults. To better understand how this newly approved therapy fits into clinical practice, what the data show and which patients are likely to benefit, we spoke with Dr Jennifer Soung (Harbor University of California, Los Angeles and Southern California Dermatology, Santa Ana, CA, USA), a key investigator on the phase 3 ARRECTOR trial.

Cantharidin solution (0.7%) drug-device combination and its use in molluscum contagiosum: James Del Rosso

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 10th 2024

Molluscum contagiosum, a common skin infection caused by a poxvirus (molluscum contagiosum virus), usually resulting in benign, mild skin disease characterized by lesions appearing anywhere on the body. In this interview, Dr. James Del Rosso (JDR Dermatology Research, Las Vegas, Nevada, USA, and President-Elect American Acne & Rosacea Society) shares insights into molluscum contagiosum, and addresses the current unmet needs in its treatment. Dr. Del Rosso also provides an in-depth look at the cantharidin solution (0.7%) drug-device combination, discussing its role and effectiveness in treating this condition.

Watch the expert perspective interview with Dr James Del Rosso on the efficacy and safety findings from CAMP-1 and CAMP-2 and cantharidin solution (0.7%) FDA approval.

Questions:

  1. Could you tell us a little about molluscum contagiosum and the unmet needs in its treatment?
  2. Could you describe the cantharidin solution (0.7%) drug-device combination?

Disclosures: James Del Rosso is a consultant and speaker for Verrica pharmaceuticals.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup